共 62 条
[1]
Rowinsky EK(1995)Paclitaxel (taxol) N Engl J Med 332 1004-1014
[2]
Donehower RC(2001)Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur J Cancer 37 1590-1598
[3]
Gelderblom H(1990)Hypersensitivity reactions from taxol J Clin Oncol 8 1263-1268
[4]
Verweij J(2009)Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer Int J Nanomedicine 4 99-105
[5]
Nooter K(2006)Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin Cancer Res 12 1317-1324
[6]
Sparreboom A(2005)Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in woman with breast cancer J Clin Oncol 23 7794-7803
[7]
Weiss RB(2008)Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642-1649
[8]
Donehower RC(2008)Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663-1671
[9]
Wiernik PH(2005)Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies J Clin Oncol 23 7785-7793
[10]
Miele E(2009)Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J Clin Oncol 27 3611-3619